WO2012177008A2 - 마이크로 rna를 포함하는 색소형성 조절용 조성물 - Google Patents
마이크로 rna를 포함하는 색소형성 조절용 조성물 Download PDFInfo
- Publication number
- WO2012177008A2 WO2012177008A2 PCT/KR2012/004645 KR2012004645W WO2012177008A2 WO 2012177008 A2 WO2012177008 A2 WO 2012177008A2 KR 2012004645 W KR2012004645 W KR 2012004645W WO 2012177008 A2 WO2012177008 A2 WO 2012177008A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pigmentation
- composition
- expression
- gene
- mirna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Definitions
- the present invention relates to the identification of hsa ⁇ miR—125b (hereinafter miR-125b), which regulates pigmentation and regulates the expression of pigmentation genes, miR ⁇ 125b or its It relates to a whitening cosmetic or pharmaceutical composition comprising a mimic and an anti-hair care cosmetic or pharmaceutical composition comprising an inhibitor of miR-125b.
- miR-125b hsa ⁇ miR—125b
- miRNA is a type of 20-25 nucleic acid (endogenous small RNA) that exists in cells and is derived from DNA that does not synthesize proteins and is produced from hairpin-shaped transcripts. do.
- the miRNA binds to the complementary sequence of the 3'-UTR of the target mRNA and induces translation inhibition or destabilization of the mRNA and ultimately acts as a repressor to inhibit protein synthesis of the target mRNA.
- One miRNA targets several mRNAs, and mRNAs are known to be regulated by multiple miRNAs.
- miRNAs are of great interest in the life sciences, as they are known to play an important role in many biological processes, including developmental periods, apoptosis, fat metabolism, and hematopoietic cell differentiation.
- the research on miRNA's role in diseases and developmental processes such as cancer is relatively progressed, but the research on miRNA's role in dermatology is relatively small.
- miR-203 suppresses the differentiation ability by targeting p63 mRNA in keratinocytes, and miR-125b inhibits the stem cell differentiation and inhibits the division of keratinocytes. Little is known about skin-specific miRNAs and functions.
- miRNA in addition to miR ⁇ 203 and miR-125b, several specific miRNAs will also play a biologically important role in skin.
- miRNA can be applied in various fields such as biological markers and materials, the research of miRNA in skin is expected to be applicable to cosmetics and pharmaceutical industries.
- the skin is largely divided into epidermis and dermis.
- the melanocytes present in the epidermis are synthesized with pigments (melanin) to give a unique color of the skin.
- Biological factors that control skin pigments are largely expressed in pigmented cells. It can be divided into two elements, a melanosome-forming element and a melanosome-carrying element.
- the most well-known factors in making melanosomes are tyrosinase (TYR).
- Rab27a is known as a factor involved in the transport of melanosomes.
- transcription factors such as PAX3 and MITF are also regulated. It is known to participate in the process. These pigmentation factors are thus important targets for skin whitening, wart formation or white hair prevention.
- the present inventors have conducted a search for miRNAs involved in pigmentation in WM266-4 melanoma cells with high expression of pigmentation genes in the skin. As a result, hsa ⁇ miR—125b inhibits the expression of tyrosinase mRNA, It was found to regulate pigmentation.
- an object of the present invention is to provide a composition having a whitening effect including miR-125b or a mimic thereof.
- an object of the present invention is to provide a composition having a white hair preventing effect comprising an inhibitor of miR-125b.
- the present invention provides a composition for controlling pigmentation and pigmentation gene expression comprising rruRNA of SEQ ID NO: 1 as an active ingredient.
- the composition for the regulation of pigmentation and pigmentation gene expression comprising the antisense nucleic acid molecule of SEQ ID NO: 2 as an active ingredient, characterized in that it has a base sequence complementary to the miRNA of SEQ ID NO: 1 can be hybridized to the miRNA to provide.
- the present invention is a method for controlling the pigmentation gene expression for the test substance, and screening a substance for controlling the pigmentation, (a) transfecting a cell with a miRNA of SEQ ID NO: 1 or an antisense nucleic acid molecule of SEQ ID NO: 2 to the cell (transfection); (b) treating the cell with a test substance; And (c) confirming whether the test substance inhibits or promotes expression of a pigmentation gene; It provides a method for screening the pigmentation and pigmentation gene expression control material comprising; (d) confirming that the color of the cell changes.
- composition comprising the miRNA of SEQ ID NO: 1 or the antisense nucleic acid molecule of SEQ ID NO: 2 of the present invention controls the expression of tyrosinase mRNA, a pigmentation gene, and has a whitening effect or anti-white hair effect by controlling pigmentation.
- a composition can be provided.
- FIG. 1 transfects an oligonucleotide having the same sequence as hsa-miR-125b into cells to induce overexpression of hsa-miR_125b and perform real-time PCR It shows the result of confirming the amount of tyrosinase mRNA expression (TYR: tyrosinase).
- FIG. 2 transfects oligonucleotides having the same sequence as hsa-miR-125b into cells to induce overexpression of hsa-miR-125b and perform western blot
- TERT tyrosinase
- oligonucleotide having a sequence complementary to hsa-iniR-125b to bind to miR-125b present in the cell to inhibit its function
- real-time PCR is performed to perform tyrosina It shows the result of confirming the amount of a mRNA mRNA expression (TYR: tyrosinase).
- FIG. 4 can induce an increase in the expression of pigmentation-related genes by measuring forskolin, which is known to increase the expression of pigmentation-related genes in the WM266-4 cell line, and measure the expression level of miR-125b.
- MiRNA real-t ime PCR was performed to confirm the expression level of niR-125b with increasing forskolin treatment concentration.
- Figure 5 is guided by the transfected hsa-miR eu overexpression phenomenon of 125b (overexpression) a nucleic acid (oligonucleotide) oligonucleotide having the same sequence and hsa-miR- 125b into a cell in a human-derived dye-forming cells (human primary melanocyte)
- human-derived dye-forming cells human primary melanocyte
- the present invention provides a miRNA of SEQ ID NO: 1 that regulates pigmentation and regulates the expression of a pigment forming gene.
- the pigmentation gene of the present invention is tyrosinase mRNA.
- the r RNA used in the present invention has a nucleotide sequence of SEQ ID NO: 1, and is a ligonucleic acid molecule consisting of 22 consecutive nucleotide sequences including cccugag.
- SEQ ID NO: 1 regulates pigmentation and pigmentation genes It may include those that perform a function of regulating the expression of.
- the miRNA may inhibit pigmentation and inhibit expression of genes involved in pigmentation.
- an oligonucleotide having the same sequence as hsa_miR-125b may be prepared by mimicing hsa-miR ′ 125b using miRNA of SEQ ID NO: 1.
- mimics of hsa-miR-125b may include those that include the hsa-miR ⁇ 125b nucleotide sequence, and controls the pigmentation and regulates the expression of pigmentation genes.
- An embodiment of the present invention provides an antisense nucleic acid molecule of SEQ ID NO: 2 having a nucleotide sequence complementary to the miRNA of SEQ ID NO: 1 and capable of hybridizing to the miRNA.
- the antisense nucleic acid molecule of SEQ ID NO: 2 can be hybridized to the miRNA as an inhibitor of miR-125b.
- the base sequence of SEQ ID NO: 2, which is an inhibitor of miR-125b may include those that can be hybridized to the miRNA.
- the present invention provides a pigment formation regulation and pigmentation regulation composition comprising the miRNA of SEQ ID NO: 1 or the antisense nucleic acid molecule of SEQ ID NO: 2 as an active ingredient.
- composition of the present invention is a composition that inhibits or promotes the expression of pigmentation genes, the pigmentation genes are tyrosinase mRNA.
- composition of the present invention inhibits or promotes pigmentation
- the miRNA is selected from the nucleotide sequences of SEQ ID NO: 1 and includes an active ingredient selected from oligonucleic acid molecules consisting of 22 consecutive nucleotide sequences including cccugag. ⁇ It may also include those that include the nucleotide sequence of SEQ ID NO: 1 and controls the pigmentation and regulates the expression of pigmentation genes.
- the composition of the present invention includes the antisense nucleic acid molecule is selected from the oligonucleic acid molecule consisting of 22 consecutive nucleotide sequences selected from the nucleotide sequence of SEQ ID NO: 2 as an active ingredient.
- the antisense nucleic acid molecule can be hybridized to the miRNA as an inhibitor of miR-125b.
- the base sequence of SEQ ID NO: 2 may include those that may be hybridized to the miRNA.
- the present invention provides a miRNA of SEQ ID NO: 1, an antisense nucleic acid molecule of SEQ ID NO: 2, or an oligonucleic acid molecule comprising a nucleotide sequence of SEQ ID NO: 1 or 2 with respect to the total weight of the composition.
- composition comprising the oligonucleic acid oligonucleotide comprising the miRNA of SEQ ID NO: 1 or the nucleotide sequence of SEQ ID NO: 1 as an active ingredient may provide a skin whitening effect by inhibiting the expression of pigment-forming genes, in particular tyrosinase mRNA. Can be. .
- composition comprising an antisense nucleic acid molecule of SEQ ID NO: 2 or an oligonucleotide comprising the nucleotide sequence of SEQ ID NO: 2 may provide a white hair prevention effect by promoting the expression of pigmentation genes, in particular tyrosinase mRNA.
- composition of the present invention is not particularly limited in the form of the formulation, but may be preferably formulated in the form of a cosmetic composition or a pharmaceutical composition.
- composition of the present invention when it is a cosmetic formulation, it contains a cosmetically acceptable medium or base.
- a cosmetically acceptable medium or base for example emulsions, suspensions / microemulsions, microcapsule, microgranules or ionic (liposomes) obtained by dispersing an oil phase in a solution, gel, solid or pasty anhydrous product, water phase.
- ionic vesicle dispersants or in the form of creams, skins, lotions, powder ointments, sprays or cone sticks.
- These compositions can be prepared according to conventional methods in the art.
- the composition of the present invention is a pharmaceutical composition
- the miRNA of SEQ ID NO: 1 or the antisense nucleic acid molecule of SEQ ID NO: 2, or an oligonucleotide comprising the nucleotide sequence of SEQ ID NO: 1 or 2 is an active ingredient. It may be formulated as a parenteral administration (injection, transdermal or external application) in the form of a solid, semi-solid or liquid by adding a commercially available inorganic or organic carrier. Preparations for parenteral administration include topical injectable preparations, ointments, lotions, sprays, suspensions, and the like.
- compositions according to an embodiment of the present invention can be easily formulated according to the conventional method, surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspensions, other commercial Supplements can be used as appropriate.
- the dosage of miRNA according to one embodiment of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dose determination based on these factors is within the level of those skilled in the art and can be applied at the level of those skilled in the art by external application on the pigmented portion for the non-injectable preparations, and in the case of injections, the By injection.
- the miRNA of the present invention may be composed of modified nucleic acid molecules.
- nucleic acid molecules including 2 1 -substituted ribose, such as, for example, 2'-0 one alkyl (e.g. methyl, ethyl), 2'-0_allyl, 2'-0-allyl can do. It may also comprise partially or wholly nucleic acid molecules with substituted bases.
- 2 1 -substituted ribose such as, for example, 2'-0 one alkyl (e.g. methyl, ethyl), 2'-0_allyl, 2'-0-allyl can do. It may also comprise partially or wholly nucleic acid molecules with substituted bases.
- One embodiment of the present invention a method for screening a substance that controls the expression of a pigment forming gene for a test substance, (a) transfecting a cell with a miRNA of SEQ ID NO: 1 or an antisense nucleic acid molecule of SEQ ID NO: 2 to the cell Making a step; (b) treating the cell with a test substance; (c) confirming whether the test substance inhibits or promotes expression of pigment forming genes; (d) checking whether the color of the cell changes; provides a method for screening a pigment-forming ⁇ -clause and a color-forming gene for expression regulation.
- the transfection may be performed using micro-injection, calcium phosphate co-precipitation, electroporation or liposomes. It may be carried out by way of example, but is not limited thereto.
- whether to regulate the expression of the pigmentation gene is a method well known in the art RT-PCR or ELISA and Western blot (i ⁇ uno blot) Can be determined using.
- Expression control material screening using the expression level of the pigment forming genes is to determine whether the test substance inhibits or promotes the expression of the pigment forming genes by immunoassay (for example, ELISA or I ⁇ unoblot) It can be done by the method.
- immunoassay for example, ELISA or I ⁇ unoblot
- the test substance is a cell It provides a method for screening substances regulating pigmentation and expression regulation of pigmentation genes, characterized in that it is determined to be a pigmentation gene inhibitor when reducing the pigmentation or reducing the expression, activity or function of the pigmentation gene. do.
- a mimic of -125b was used, and the mimic of hsa-miR-125b is an oligonucleotide having the same sequence as hsa miR-125b and transfected into cells to overexpress phenomena of hsa-miR-125b. overexpression).
- Mimic of hsa-miR-125b in myeloma cell line ⁇ 266 ⁇ 4 (trade name: 0300595—03-0005, miRIDIAN Mimic, Human hsa-miR-125b MI MAT0000423 / M 10000446 (hs am i R-125b), 5 nmol, product of Dharmacon, Inc.
- Example 1 was transfected with liposomes to a concentration of 20 uM and 0 ⁇ shifted into cells.
- Control oligonucleotide sample without any oligonucleic acid (Comparative Example 1) and oligonucleic acid that does not overlap at all with the miRNA sequence of the present invention (trade name: CN-001000-01-05, miRIDIAN microR A Mimic Negative Control # 1, Dharmacon , Inc. was used as a sample (Comparative Example 2).
- the cells were incubated in a 37 ° C. 5% C0 2 incubator for about 60 hours and RNA was isolated using 1 ml of H-Trizol reagent.
- the present inventors used the misa of hsa-miR-125b for gain-of-funct ional study of hsa-miR-125b, and the misa-miR-125b mimics the hsa-miR-125b.
- Transduction into cells with oligonucleotides having the same sequence can induce overexpression of hsa-miR-125b.
- Mimic of hsa ⁇ miR-125b in melanoma cell line WM266-4 (trade name: 0300595—03 ⁇ 0005, miRIDIAN Mimic, human hsa-miR-125b MI MAT0000423 / M 10000446 (hs am i-125b), 5 ⁇ ol Example 1) is transfected with liposomes to a concentration of 20 uM and transferred into cells.
- the control group was a sample without any Lollinucleic acid (Comparative Example 1) and the oligonucleic acid (brand name: CN ⁇ 001000-01 ⁇ 05, miRIDIAN microRNA Mimic Negative Control # 1, Dharmacon) which did not overlap at all with the miRNA sequence of the present invention. (Comparative Example 2) was used. About 60 hours after transfection, the cell membrane was broken using RIPA buffer, the supernatant containing protein was extracted using a centrifuge, and about 10 grams of protein was quantified by BCA method. Western blot experiments were performed with the quantified protein, and the amount of tyrosinase protein was observed using an antibody specific for tyrosinase (upstate 05-647). Tyrosinase protein expression level was normalized to the protein expression level of the housekeeping gene GAPDH, the results are shown in FIG.
- the present inventors used an inhibitor of miR-124b for the loss-of-funct ional study of miR-125b.
- the inhibitor of miR-125b is a lygonucleic acid having a complementary sequence of miR ⁇ 125b. It can bind to miR-125b present in the cell and inhibit its function.
- MiR-125b inhibitor (Liname: IH-300595-05 ⁇ 0005, miRIDIAN Hairpin Inhibitor, Human hsa-miR-125b MIMAT0000423 / MI0000446 (hsa-mi-125b), Dharmacon, Inc .; Example 2) was transfected with liposomes to a concentration of 75 uM and transferred into cells.
- the control group was a sample transfected with oligonucleic acid (trade name: CN-001000—01-05, product of miRIDIAN microRNA Mimic Negative Control # 1, manufactured by Dharmacon, Inc.), which did not overlap with the inhibitor of miRNA of the present invention (Comparative Example).
- tyrosinase mRNA expression level was normalized by mRNA expression level of GAPDH, which is a housekeeping gene (assay ID: 4333764F), and the results are shown in FIG. 3.
- the present inventors treated with forskolin, which is known to increase the expression level of pigment-forming genes, to induce conditions for increasing the expression level of pigment-forming genes by forskolin, and then expressed the basic expression of hsa-miR-125b present in cells. It was confirmed whether the amount changed.
- hsa ⁇ miR-125b-specific stem-loop primers and reverse transcriptase to make hsa-miR- 125b-specific cDNA; hsa ⁇ mR-125b-specific primers to hsa -miR-125b mRNA expression level was observed.
- the expression level of hsa-miR-125b mRNA was normalized to the expression of small RNA of rnu6b, a housekeeping gene, and the results are shown in FIG. 4.
- the present inventors obtained a gain-of-funct ional study of hsa-miR-125b.
- the hsa-miR-125b mimetics were used, and the misa of hsa-miR-125b were transfected into cells with ol igonucleotide having the same sequence as hsa_miR_125b and overexpression of hsa_miR-125b. (overexpression) can be induced.
- Mimetics of hsa-miR-125b on human primary melanocytes (trade name: C— 300595-03-0005, miRIDIAN Mimic, human hsa-miR- 125b MIMAT0000423 / MI0000446 (hsa-miR-125b), 5 nmol, Dharmacon, Inc .; Example 1) is transfected into a cell at a concentration of 20 uM with a dodotox liposome.
- the control group is a sample without any oligonucleotide (Comparative Example 1) and an oligonucleic acid that does not overlap at all with the miRNA sequence of the present invention (trade name: CN-001000—01-05, miRIDIAN microRNA Mimic Negative Control # 1, Dharmacon, Inc.). product) was used for sample i (Comparative example 2) during transfection. After 7 days after transfection, wash the cells twice with 5 ml of PBS complete solution, add 1 ml of PBS complete solution, scrape all the cells using a scraper, and then scrape the cells at 13000 rpm. After centrifugation (minrifugation) for a minute to make a cell pellet (cell pellet) and the color of the cell pellets were observed to compare the degree of pigment formation. And the observation result is shown in FIG.
- the skin whitening composition containing the miRNA of SEQ ID NO: 1 as an active ingredient according to the present invention may be prepared as in the following formulation example, but is not limited thereto.
- composition shown in Table 1 it can be prepared by the conventional method.
- composition shown in Table 2 it can be prepared nutrition lotion in a conventional manner.
- Massage creams may be prepared by conventional methods according to the compositions described in Table 4 below.
- the pack may be prepared by conventional methods according to the compositions described in Table 5 below. [Table 5]
- Ointments may be prepared by conventional methods according to the compositions shown in Table 6 below.
- the hair composition for preventing white hair containing the miRNA of SEQ ID NO: 2 according to the present invention as an active ingredient may be prepared as in the following formulation example, but is not limited thereto.
- Hair conditioning can be prepared by conventional methods according to the compositions described in Table 8 below.
- the scalp hair tonic may be prepared by a conventional method according to the composition described in Table 9.
- Injectables can be prepared by conventional methods according to the compositions set forth in Table 11 below.
- Table 12 According to the composition shown in Table 12 can be prepared ointment in a conventional manner.
- the lotion may be prepared by a conventional method according to the composition described in Table 13.
- Sprays can be prepared by conventional methods according to the compositions set forth in Table 14 below.
- SEQ ID NO: 1 is a nucleotide sequence of miRNA that regulates the expression of a pigment forming gene used in the present invention, consisting of 22 consecutive nucleotide sequences including cccugag.
- SEQ ID NO: 2 can be hybridized to miR-125b used in the present invention as an inhibitor of miR-125b used in the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280030667.5A CN104169420B (zh) | 2011-06-23 | 2012-06-13 | 包含miRNA的调节色素形成的组合物 |
US14/126,505 US9303261B2 (en) | 2011-06-23 | 2012-06-13 | Composition for controlling chromogenesis including microRNA |
HK14112601.0A HK1199063A1 (zh) | 2011-06-23 | 2014-12-16 | 包含 的調節色素形成的組合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110061107 | 2011-06-23 | ||
KR10-2011-0061107 | 2011-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012177008A2 true WO2012177008A2 (ko) | 2012-12-27 |
WO2012177008A3 WO2012177008A3 (ko) | 2013-02-14 |
Family
ID=47423053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/004645 WO2012177008A2 (ko) | 2011-06-23 | 2012-06-13 | 마이크로 rna를 포함하는 색소형성 조절용 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9303261B2 (ko) |
KR (1) | KR101938548B1 (ko) |
CN (1) | CN104169420B (ko) |
HK (1) | HK1199063A1 (ko) |
WO (1) | WO2012177008A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018056583A1 (ko) * | 2016-09-23 | 2018-03-29 | (주)아모레퍼시픽 | Sh3bp4 억제 물질을 포함하는 피부 미백용 조성물 및 sh3bp4 억제 물질의 스크리닝 방법 |
KR102109976B1 (ko) | 2017-07-25 | 2020-05-13 | 동국대학교 산학협력단 | 아르기나제 2 억제제를 유효성분으로 함유하는 색소형성 억제용 조성물 |
EP3724208A4 (en) | 2017-12-15 | 2021-09-01 | Flagship Pioneering Innovations VI, LLC | COMPOSITIONS WITH CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF |
CN111041082B (zh) * | 2018-10-11 | 2023-11-07 | 伽蓝(集团)股份有限公司 | 一种以皮肤光老化靶标筛选改善皮肤光老化的活性物的方法及改善皮肤光老化的活性物 |
IL311628A (en) * | 2019-03-01 | 2024-05-01 | Flagship Pioneering Innovations Vi Llc | Polyribonucleotides and their cosmetic uses |
CN110448567A (zh) * | 2019-08-26 | 2019-11-15 | 佳木斯大学 | miRNA125b纳米粒子的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7504385B2 (en) * | 2003-12-17 | 2009-03-17 | Avon Products, Inc. | si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation |
US20110143948A1 (en) * | 2008-02-01 | 2011-06-16 | Ranjan Perera | Molecular signatures and biomarkers associated with melanoma and methods of use thereof |
KR20110068061A (ko) * | 2009-12-15 | 2011-06-22 | 주식회사 코리아나화장품 | 티로시나제의 발현을 저해하는 siRNA 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2428568B1 (en) * | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
GB0502042D0 (en) * | 2005-02-01 | 2005-03-09 | Univ Glasgow | Materials and methods for diagnosis and treatment of chronic fatigue syndrome |
EP2145001A2 (en) | 2006-09-19 | 2010-01-20 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
TWI382849B (zh) * | 2007-10-29 | 2013-01-21 | Mello Biotech Taiwan Co Ltd | 產生藉由基因靜默效應以用於皮膚維護之化妝品的方法以及編碼基因靜默效應物之基因重組核苷酸 |
JP2011505143A (ja) * | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロrna発現プロファイリング及び肺癌における末梢血ターゲティング |
CN101942502B (zh) * | 2009-12-24 | 2014-09-17 | 北京命码生科科技有限公司 | 胰腺癌标记物及其检测方法、试剂盒和生物芯片 |
-
2012
- 2012-06-11 KR KR1020120061988A patent/KR101938548B1/ko active IP Right Grant
- 2012-06-13 US US14/126,505 patent/US9303261B2/en active Active
- 2012-06-13 CN CN201280030667.5A patent/CN104169420B/zh active Active
- 2012-06-13 WO PCT/KR2012/004645 patent/WO2012177008A2/ko active Application Filing
-
2014
- 2014-12-16 HK HK14112601.0A patent/HK1199063A1/zh not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7504385B2 (en) * | 2003-12-17 | 2009-03-17 | Avon Products, Inc. | si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation |
US20110143948A1 (en) * | 2008-02-01 | 2011-06-16 | Ranjan Perera | Molecular signatures and biomarkers associated with melanoma and methods of use thereof |
KR20110068061A (ko) * | 2009-12-15 | 2011-06-22 | 주식회사 코리아나화장품 | 티로시나제의 발현을 저해하는 siRNA 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물 |
Non-Patent Citations (2)
Title |
---|
DAVID TS WU ET AL.: 'Mir 434-5p mediates skin whitening and lightening' CLIN COSMET INVESTING DERMATOL. vol. 1, 2008, pages 19 - 35 * |
Z. ZHU ET AL.: 'MicroRNA-25 functions in regulation of pigmentation by targeting the transcription factor MITF in alpaca (Lama pacos) skin' DOMESTIC ANIMAL ENDOCRINOLOGY vol. 38, 2010, pages 200 - 209 * |
Also Published As
Publication number | Publication date |
---|---|
CN104169420B (zh) | 2016-05-04 |
KR101938548B1 (ko) | 2019-01-15 |
CN104169420A (zh) | 2014-11-26 |
KR20130001123A (ko) | 2013-01-03 |
US20140134636A1 (en) | 2014-05-15 |
WO2012177008A3 (ko) | 2013-02-14 |
US9303261B2 (en) | 2016-04-05 |
HK1199063A1 (zh) | 2015-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012177008A2 (ko) | 마이크로 rna를 포함하는 색소형성 조절용 조성물 | |
US8455518B2 (en) | Method of treating skin with microRNA modulators | |
US10508140B2 (en) | Peptide having hair growth-promoting activity and/or melanin generation-promoting activity, and use thereof | |
KR101849102B1 (ko) | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 | |
Springhorn et al. | Transcriptional regulation in cardiac muscle. Coordinate expression of Id with a neonatal phenotype during development and following a hypertrophic stimulus in adult rat ventricular myocytes in vitro. | |
US9045753B2 (en) | siRNA molecule for inhibiting growth of melanin and application thereof | |
KR102552776B1 (ko) | miRNA를 포함하는 흑색종 전이 억제용 조성물 | |
JP6230545B2 (ja) | 皮膚の色素沈着に影響するマイクロrna分子の使用 | |
JP2019529462A (ja) | Tnfrsf 14抑制物質を含む皮膚美白用組成物及びtnfrsf 14抑制物質のスクリーニング方法 | |
KR101871920B1 (ko) | 마이크로 rna를 포함하는 조성물 | |
CN110022849B (zh) | 包含sh3bp4抑制物质的皮肤美白组合物及sh3bp4抑制物质的筛查方法 | |
KR101800243B1 (ko) | 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물 | |
KR101852440B1 (ko) | 듀옥스 2 miRNA를 포함하는 피부 세포 분화 조절용 조성물 | |
KR102027451B1 (ko) | 마이크로 rna 및 이를 사용하는 스크리닝 방법 | |
KR20120139430A (ko) | 마이크로 rna를 포함하는 조성물 | |
KR102682748B1 (ko) | Sh3bp4 억제 물질을 포함하는 피부 미백용 조성물 및 sh3bp4 억제 물질의 스크리닝 방법 | |
CN117462684A (zh) | Slc1a4在制备治疗色素沉着异常性皮肤病药物中的应用 | |
KR101309335B1 (ko) | 콜라겐 조절용 조성물 | |
JP2015134723A (ja) | アセチル化酵素競合阻害因子Gm16515の新規用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280030667.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12802909 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14126505 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 10-04-2014 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 10-04-2014 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12802909 Country of ref document: EP Kind code of ref document: A2 |